Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Immunol ; 163(2): 1037-44, 1999 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-10395702

RESUMO

Twenty-two new HLA-A2.1-binding peptides derived from the protooncogene HER2/neu were identified and analyzed for their capacity to elicit peptide and tumor-specific CTL responses. We used peptide-pulsed autologous DC from the ascites of patients with ovarian carcinomas to induce CTL. Of the 22 tested new HER2/neu-derived epitopes that could bind HLA-A2 with high (IC50 < 50 nM) or intermediate (50 nM < IC50 < 500 nM) affinity, we report the recognition by CTL of at least four novel epitopes, including HER2(9435), HER2(9665), HER2(9689), and HER2(10952), and confirm that of the known HER2 (9369) epitope. These epitopes were able to elicit CTL that specifically killed peptide-sensitized target cells and, most importantly, a HER2/neu-transfected cell line and the autologous tumor cells. We also confirm that HER2/neu is overexpressed in several melanoma lines, and as a new finding, report that some of these lines are sensitive to CTL induced by the HER2 (9369), HER2(9435), and HER2(9689) epitopes. Finally, CTL clones specific for HER2 (9369), HER2(9435), and HER2(9689) epitopes were isolated from tumor-specific CTL lines, further demonstrating the immunodominance of these epitopes. These findings broaden the potential application of HER2/neu-based immunotherapy.


Assuntos
Carcinoma/imunologia , Citotoxicidade Imunológica , Epitopos de Linfócito T/imunologia , Melanoma/imunologia , Oligopeptídeos/imunologia , Receptor ErbB-2/imunologia , Linfócitos T Citotóxicos/imunologia , Carcinoma/genética , Carcinoma/metabolismo , Carcinoma/terapia , Separação Celular , Neoplasias do Colo , Testes Imunológicos de Citotoxicidade , Epitopos de Linfócito T/isolamento & purificação , Epitopos de Linfócito T/metabolismo , Feminino , Antígeno HLA-A2/biossíntese , Humanos , Ativação Linfocitária , Melanoma/genética , Melanoma/metabolismo , Melanoma/terapia , Oligopeptídeos/síntese química , Oligopeptídeos/metabolismo , Neoplasias Ovarianas , Receptor ErbB-2/biossíntese , Receptor ErbB-2/genética , Receptor ErbB-2/isolamento & purificação , Linfócitos T Citotóxicos/metabolismo , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...